Global Information
회사소개 | 문의 | 비교리스트

주요 30개 암 치료제 제조업체(2019년)

Top 30 Oncology Drugs Manufacturers 2019: AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies

리서치사 Visiongain Ltd
발행일 2019년 05월 상품 코드 886197
페이지 정보 영문 157 Pages
가격
£ 3,499 ₩ 5,636,000 Unprintable PDF (Single User) - 1 Year License help
1명만 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC 1대에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄 또한 불가능합니다.
£ 3,899 ₩ 6,280,000 PDF (Departmental - 5 Users) - 1 Year License help
동일 사업장(소재지) 내 5명까지 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF파일은 Copy & Paste가 되지 않으며, 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 4,999 ₩ 8,052,000 PDF (Site License) help
동일 사업장(소재지) 내 모든 분이 이용할 수 있는 라이센스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 되지 않습니다. DRM(디지털 저작권 관리시스템)은 적용되어 있지 않지만, PDF 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 6,999 ₩ 11,274,000 PDF (Global License - Includes Free Datasets)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



주요 30개 암 치료제 제조업체(2019년) Top 30 Oncology Drugs Manufacturers 2019: AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies
발행일 : 2019년 05월 페이지 정보 : 영문 157 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 암 치료제(Oncology Drugs) 시장을 조사했으며, 암의 생리학적 개요, 이환율 및 유병률, 암치료 유형과 개요, 암 치료제 시장 정성 분석, 주요 제조업체 개요, 제품 포트폴리오, 최근 전개 등을 정리했습니다.

제1장 보고서 개요

제2장 서론 : 암 치료제

  • 암의 생리학 : 원인과 영향
  • 제어 불능한 성장
  • 탈분화
  • 침습성과 전이
  • 암의 원인
  • 암 이환율 및 유병률 : 세계 동향
  • 이환율
  • 사망률
  • 생존률
  • 고도로 발전한 세계
  • 종양 치료
  • 화학요법
  • 호르몬요법
  • 면역요법
    • 단클론항체
    • 암백신
    • 비특이적 면역요법
    • 표적요법
    • 약제 차별화

제3장 정성 분석

  • SWOT 분석
  • STEP 분석

제4장 주요 기업

  • AstraZeneca Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Amgen Inc.
  • BRISTOL-MYERS SQUIBB
  • GlaxoSmithKline PLC(GSK Consumer Care)
  • Johnson & Johnson
  • F. HOFFMANN-LA ROCHE AG
  • Eli Lilly and Company
  • Celgene Corporation
  • Pfizer Inc.
  • Astellas Pharma Inc.
  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • Sanofi S.A.(Sanofi Genzyme)
  • Takeda Pharmaceutical Company Ltd.
  • Gilead Science, Inc.
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • FRESENIUS KABI AG
  • GRIFOLS S.A.
  • Boehringer Ingelheim GMBH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • ZIOPHARM Oncology, Inc.
  • Sorrento Therapeutics, Inc.
  • Aurora Biopharma, Inc.
  • Tessa Therapeutics Pte Ltd.
  • Jounce Therapeutics, Inc.
  • Mylan N.V.
    • 기업 개요
    • 제품 포트폴리오
    • 최근 전개

부록

LSH 19.07.18

List of Tables

  • Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2017
  • Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2017
  • Table 3.1 Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market
  • Table 3.2 Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2017
  • Table 4.1 AstraZeneca Plc: Company Overview
  • Table 4.2 AstraZeneca Plc: Product Portfolio
  • Table 4.3 AstraZeneca Plc: Recent Developments
  • Table 4.4 Merck & Co. Inc.: Company Overview
  • Table 4.5 Merck & Co. Inc.: Product Portfolio
  • Table 4.6 Merck & Co. Inc.: Recent Developments
  • Table 4.7 Novartis AG: Company Overview
  • Table 4.8 Novartis AG: Product Portfolio
  • Table 4.9 Novartis AG: Recent Developments
  • Table 4.10 Amgen Inc.: Company Overview
  • Table 4.11 Amgen Inc.: Product Portfolio
  • Table 4.12 Amgen Inc.: Recent Developments
  • Table 4.13 BRISTOL-MYERS SQUIBB: Company Overview
  • Table 4.14 BRISTOL-MYERS SQUIBB: Product Portfolio
  • Table 4.15 BRISTOL-MYERS SQUIBB: Recent Developments
  • Table 4.16 GlaxoSmithKline PLC: Company Overview
  • Table 4.17 GlaxoSmithKline PLC: Product Portfolio
  • Table 4.18 GlaxoSmithKline PLC: Recent Developments
  • Table 4.19 Johnson & Johnson: Company Overview
  • Table 4.20 Johnson & Johnson: Product Portfolio
  • Table 4.21 Johnson & Johnson: Recent Developments
  • Table 4.22 F. Hoffmann-La Roche: Company Overview
  • Table 4.23 F. Hoffmann-La Roche: Product Portfolio
  • Table 4.24 F. Hoffmann-La Roche: Recent Developments
  • Table 4.25 Eli Lilly and Company: Company Overview
  • Table 4.26 Eli Lilly and Company: Product Portfolio
  • Table 4.27 Eli Lilly and Company: Recent Developments
  • Table 4.28 Celgene Corporation: Company Overview
  • Table 4.29 Celgene Corporation: Product Portfolio
  • Table 4.30 Celgene Corporation: Recent Developments
  • Table 4.31 Pfizer Inc.: Company Overview
  • Table 4.32 Pfizer Inc.: Product Portfolio
  • Table 4.33 Pfizer: Recent Developments
  • Table 4.34 Astellas Pharma, Inc.: Company Overview
  • Table 4.35 Astellas Pharma, Inc.: Recent Developments
  • Table 4.36 Abbott Laboratories Inc.: Company Overview
  • Table 4.37 Abbott Laboratories Inc.: Product Portfolio
  • Table 4.38 Abbott Laboratories Inc.: Recent Developments
  • Table 4.39 AbbVie Inc.: Company Overview
  • Table 4.40 AbbVie Inc.: Product Portfolio
  • Table 4.41 AbbVie Inc.: Recent Developments
  • Table 4.42 Sanofi S.A.: Company Overview
  • Table 4.43 Sanofi S.A.: Product Portfolio
  • Table 4.44 Sanofi S.A.: Recent Developments
  • Table 4.45 Takeda Pharmaceutical Company Ltd.: Company Overview
  • Table 4.46 Takeda Pharmaceutical Company Ltd.: Product Portfolio
  • Table 4.47 Takeda Pharmaceutical Company Ltd.: Recent Developments
  • Table 4.48 Gilead Science, Inc.: Company Overview
  • Table 4.49 Gilead Science, Inc.: Product Portfolio
  • Table 4.50 Gilead Science, Inc.: Recent Developments
  • Table 4.51 A. Menarini Industrie Farmaceutiche Riunite Srl : Company Overview
  • Table 4.52 A. Menarini Industrie Farmaceutiche Riunite Srl : Recent Developments
  • Table 4.53 FRESENIUS KABI AG: Company Overview
  • Table 4.54 FRESENIUS KABI AG: Product Portfolio
  • Table 4.55 FRESENIUS KABI AG: Recent Developments
  • Table 4.56 Grifols S.A.: Company Overview
  • Table 4.57 Grifols S.A.: Product Portfolio
  • Table 4.58 Boehringer Ingelheim GMBH: Company Overview
  • Table 4.59 Boehringer Ingelheim GMBH: Product Portfolio
  • Table 4.60 Boehringer Ingelheim GMBH: Recent Developments
  • Table 4.61 Sun Pharmaceutical Industries Ltd.: Company Overview
  • Table 4.62 Sun Pharmaceutical Industries Ltd.: Product Portfolio
  • Table 4.63 Sun Pharmaceutical Industries Ltd.: Recent Developments
  • Table 4.64 Teva Pharmaceutical Industries Ltd.: Company Overview
  • Table 4.65 Teva Pharmaceutical Industries Ltd.: Product Portfolio
  • Table 4.66 Teva Pharmaceutical Industries Ltd.: Recent Developments
  • Table 4.67 Valeant Pharmaceuticals International, Inc.: Company Overview
  • Table 4.68 Valeant Pharmaceuticals International, Inc.: Product Portfolio
  • Table 4.69 Valeant Pharmaceuticals International, Inc.: Recent Developments
  • Table 4.70 ZIOPHARM Oncology, Inc.: Company Overview
  • Table 4.71 Sorrento Therapeutics, Inc.: Company Overview
  • Table 4.72 Sorrento Therapeutics, Inc.: Recent Developments
  • Table 4.73 Aurora Biopharma, Inc.: Company Overview
  • Table 4.74 Tessa Therapeutics Pte Ltd.: Company Overview
  • Table 4.75 Tessa Therapeutics Pte Ltd.: Recent Developments
  • Table 4.76 Jounce Therapeutics, Inc.: Company Overview
  • Table 4.77 Valeant Pharmaceuticals International, Inc.: Recent Developments
  • Table 4.78 Mylan N.V.: Company Overview
  • Table 4.79 Mylan N.V.: Recent Developments

List of Figures

  • Figure 4.1 AstraZeneca Plc: Revenue, ($million), 2013-2017
  • Figure 4.2 AstraZeneca Plc: Product Segments Share (%), 2017
  • Figure 4.3 AstraZeneca Plc: Geographic Share (%), 2017
  • Figure 4.4 Merck & Co. Inc.: Revenue, ($million), 2013-2017
  • Figure 4.5 Merck & Co. Inc., Product Segments Share (%), 2017
  • Figure 4.6 Merck & Co. Inc., Geographical Presence Share (%), 2017
  • Figure 4.7 Novartis AG: Revenue, ($million), 2013-2017
  • Figure 4.8 Novartis AG, Product Segments Share (%), 2017
  • Figure 4.9 Novartis AG: Geographical Presence Share (%), 2017
  • Figure 4.10 Amgen Inc., Revenue, ($million), 2013-2017
  • Figure 4.11 Amgen Inc., Product Segments Share (%), 2017
  • Figure 4.12 Amgen Inc.: Geographical Presence Share (%), 2017
  • Figure 4.13 BRISTOL-MYERS SQUIBB: Revenue, ($million), 2013-2017
  • Figure 4.14 BRISTOL-MYERS SQUIBB: Product Segments Share (%), 2017
  • Figure 4.15 BRISTOL-MYERS SQUIBB: Geographical Presence Share (%), 2017
  • Figure 4.16 GlaxoSmithKline PLC: Revenue, ($million), 2013-2017
  • Figure 4.17 GlaxoSmithKline PLC: Product Segments Share (%), 2017
  • Figure 4.18 GlaxoSmithKline PLC: Geographical Presence Share (%), 2017
  • Figure 4.19 Johnson & Johnson: Revenue, ($million), 2013-2017
  • Figure 4.20 Johnson & Johnson: Product Segments Share (%), 2017
  • Figure 4.21 Johnson & Johnson: Geographical Presence Share (%), 2017
  • Figure 4.22 F. Hoffmann-La Roche: Revenue, ($million), 2013-2017
  • Figure 4.23 F. Hoffmann-La Roche: Product Segments Share (%), 2017
  • Figure 4.24 F. Hoffmann-La Roche, Geographical Presence Share (%), 2017
  • Figure 4.25 Eli Lilly and Company: Revenue, ($million), 2013-2017
  • Figure 4.26 Eli Lilly and Company: Product Segments Share (%), 2017
  • Figure 4.27 Eli Lilly and Company: Geographical Presence Share (%), 2017
  • Figure 4.28 Celgene Corporation, Revenue, ($million), 2013-2017
  • Figure 4.29 Pfizer Inc.: Revenue, ($million), 2013-2017
  • Figure 4.30 Pfizer Inc.: Product Segments Share (%), 2017
  • Figure 4.31 Pfizer Inc., Geographical Presence Share (%), 2017
  • Figure 4.32 Astellas Pharma, Inc.: Revenue, ($million), 2013-2017
  • Figure 4.33 Astellas Pharma, Inc.: Geographical Presence Share (%), 2017
  • Figure 4.34 Abbott Laboratories Inc.: Revenue, ($million), 2013-2017
  • Figure 4.35 Abbott Laboratories Inc.: Product Segment Share (%), 2017
  • Figure 4.36 Abbott Laboratories Inc., Geographic Presence Share (%), 2017
  • Figure 4.37 AbbVie Inc.: Revenue, ($million), 2013-2017
  • Figure 4.38 AbbVie Inc.: Product Segments Share (%), 2017
  • Figure 4.39 AbbVie Inc.: Geographical Presence Share (%), 2017
  • Figure 4.40 Sanofi S.A.: Revenue, ($million), 2013-2017
  • Figure 4.41 Sanofi S.A.: Product Segments Share (%), 2017
  • Figure 4.42 Sanofi S.A., Geographical Presence Share (%), 2017
  • Figure 4.43 Takeda Pharmaceutical Company Ltd., Revenue, ($million), 2014-2018
  • Figure 4.44 Takeda Pharmaceuticals Inc., Geographical Presence Share (%), 2018
  • Figure 4.45 Gilead Science, Inc.: Revenue, ($million), 2013-2017
  • Figure 4.46 Gilead Science, Inc., Product Segments Share (%), 2017
  • Figure 4.47 Gilead Science, Inc., Geographical Presence Share (%), 2017
  • Figure 4.48 Grifols S.A.: Revenue, ($million), 2013-2017
  • Figure 4.49 Grifols S.A., Product Segments Share (%), 2017
  • Figure 4.50 Grifols S.A., Geographical Presence Share (%), 2017
  • Figure 4.51 Boehringer Ingelheim GMBH, Revenue, ($million), 2013-2017
  • Figure 4.52 Boehringer Ingelheim GMBH, Product Segments Share (%), 2017
  • Figure 4.53 Boehringer Ingelheim GMBH, Geographical Presence Share (%), 2017
  • Figure 4.54 Sun Pharmaceutical Industries Ltd., Revenue, ($million), 2014-2018
  • Figure 4.55 Teva Pharmaceutical Industries Ltd.: Revenue, ($million), 2013-2017
  • Figure 4.56 Teva Pharmaceutical Industries Ltd.: Product Segments Share (%), 2017
  • Figure 4.57 Teva Pharmaceutical Industries Ltd., Geographical Presence Share (%), 2017
  • Figure 4.58 Valeant Pharmaceuticals International, Inc.: Revenue, ($million), 2013-2017
  • Figure 4.59 Valeant Pharmaceuticals International, Inc.: Product Segments Share (%), 2017
  • Figure 4.60 Valeant Pharmaceuticals International, Inc.: Geographical Presence Share (%), 2017
  • Figure 4.61 ZIOPHARM Oncology, Inc., Revenue, ($million), 2013-2017
  • Figure 4.62 Jounce Therapeutics, Inc.: Revenue, ($million), 2016-2017
  • Figure 4.63 Mylan N.V., Revenue, ($million), 2013-2017
  • Figure 4.64 Mylan N.V., Geographical Presence Share (%), 2017

Companies Listed

  • Abbott Laboratories, Inc.
  • AbbVie
  • Ablynx NV
  • Agios Pharmaceuticals, Inc.
  • Alcon
  • Allergan plc.
  • Allogene Therapeutics, Inc.
  • Amgen
  • ARMO BioSciences, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • AurKa Pharma, Inc.
  • Aurora Biopharma, Inc.
  • Bavarian Nordic
  • BeiGene
  • BiolineRX
  • BioNTech AG.
  • Biothera
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Calibr
  • Calico
  • Calithera Biosciences
  • Celgene Corporation
  • Celgene International Sarl
  • Ciba-Geigy
  • CytomX Therapeutics
  • Eisai Co., Ltd.
  • Eli Lilly
  • Flatiron Health
  • Flexus Biosciences, Inc.
  • Fosun Pharma
  • Foundation Medicine, Inc.
  • Fresenius Kabi AG
  • Genscript Biotech Corporation
  • Gilead Science
  • GlaxoSmithKline (GSK)
  • Harpoon Therapeutics
  • Heptares Therapeutics
  • IBM
  • IBM Watson
  • IFM Therapeutics
  • Ignyta
  • Immatics Biotechnologies
  • Janssen Diagnostics, LLC.
  • Johnson & Johnson
  • Jounce Therapeutics, Inc.
  • Juno Therapeutics, Inc.
  • Kimberly-Clark Corporation
  • Kite Pharma
  • Legend Biotech Ireland Limited
  • Legend Biotech USA Inc.
  • MD Anderson
  • MedImmune
  • Menarini Industrie Farmaceutiche Riunite Srl
  • Merck & Co.
  • Miltenyi Biotec
  • Moderna Therapeutics
  • Mylan N.V.
  • Nektar Therapeutics
  • Noile-Immune Biotech
  • Novartis
  • Ono Pharmaceutical Company
  • OSE
  • Parker Institute
  • Pfizer
  • Regeneron Pharmaceuticals, Inc
  • Rigontec
  • Roche
  • Sandoz
  • Sangamo Therapeutics
  • SARAH CANNON Research Institute
  • SCILEX
  • Selvita
  • Simcere
  • Sorrento Therapeutics, Inc.
  • Sosei Group Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Takeda
  • TerSera Therapeutics LLC
  • Tessa Therapeutics Pte Ltd.
  • Valeant Phamaceuticals International, Inc.
  • Veropharm
  • Vyriad
  • ZIOPHARM Oncology, Inc.

List of Organizations Mentioned in the Report

  • European Commission
  • European Medicines Agency
  • Food and Drug Administration (FDA)
  • Health Canada
  • Japan's Pharmaceuticals and Medical Devices Agency (PMDA)
  • Japanese Ministry of Health, Labour and Welfare
  • Johns Hopkins
  • World Child Cancer
  • World Health Organization (WHO)

Cancer treating drugs market forms the most lucrative sector in pharmaceuticals. As the ageing population continues to rise across the world, the incidence of cancer will continue to grow, leading to increased spending on cancer-treating medicines. This report lists and discusses the top 30 oncology drugs manufacturers.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 157-page report you will receive 83 tables and 64 figures-all unavailable elsewhere.

The 157-page report provides clear detailed insight into the top 30 oncology drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Assessment of the leading companies in the global oncology drugs market. The list below shows some of the companies that are discussed in the report:
  • Abbott Laboratories
  • AbbVie
  • Amgen
  • Astellas Pharma
  • AstraZeneca
  • Aurora Biophama
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • Celgene Corporation
  • Eli Lilly
  • Fresenius Kabi
  • Gilead
  • GlaxoSmithKline (GSK)
  • Grifols
  • Johnson & Johnson
  • Jounce Therapeutics
  • Other companies

image1

  • For each company, the report provides information and discussion on:
  • Company overview
  • Product portfolio
  • Recent development
  • Financial information
  • Key questions answered by this report:
  • How is the Oncology Drugs Manufacturers market evolving?
  • What is driving and restraining the Oncology Drugs Manufacturers market?
  • What will be the main driver for the overall market?
  • Will leading Oncology Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • Who are the leading players and what are their prospects over the forecast period?

Visiongain's study is intended for anyone requiring commercial analyses for the Top 30 Oncology Drugs Manufacturers 2019. You find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Global Cancer-Treating drugs Overview
  • 1.2 Research Methodology
  • 1.3 Primary Research
  • 1.4 Secondary Research
  • 1.5 Why You Should Read This Report
  • 1.6 Who is This Report For?
  • 1.7 Associated Visiongain Reports
  • 1.8 About Visiongain

2 Introduction to Cancer-Treating Drugs

  • 2.1 The Physiology of Cancer - Causes and Effects
  • 2.2 Uncontrolled Growth
  • 2.3 Dedifferentiation
  • 2.4 Invasiveness and Metastasis
  • 2.5 Causes of Cancer
  • 2.6 The Incidence and Prevalence of Cancer - Trends in the World
  • 2.7 Incidence
  • 2.8 Mortality
  • 2.9 Survival - Improving Odds
  • 2.10 The Developed World
  • 2.11 Treating Tumours - How Can We Fight Back?
  • 2.12 Chemotherapy - The Traditional Treatment
  • 2.13 Hormone Therapies
  • 2.14 Immunotherapy - A Magic Bullet?
    • 2.14.1 Monoclonal Antibodies (mAbs)
    • 2.14.2 Cancer Vaccines
    • 2.14.3 Non-Specific Immunotherapies
    • 2.14.4 Targeted Therapies
    • 2.14.5 Differentiating Agents

3 Cancer Treating Drugs Market, Qualitative Analysis

  • 3.1 SWOT Analysis of the Anti-Cancer Drugs Market
    • 3.1.1 Strengths of the Market
      • 3.1.1.1 The Rising Incidence of Cancer
      • 3.1.1.2 Ample Treatment Options Available
    • 3.1.2 Weaknesses
      • 3.1.2.1 The Challenges of Drug Development
      • 3.1.2.2 The Complex Nature of Cancer
    • 3.1.3 Opportunities in the Anti-Cancer Drugs Market
      • 3.1.3.1 The Advancement of Research
      • 3.1.3.2 A Shift Towards Personalisation
    • 3.1.4 Threats Facing the Anti-Cancer Drugs Market
      • 3.1.4.1 The Threat of Regulation
  • 3.2 STEP Analysis of the Anti-Cancer Drugs Market
    • 3.2.1 Social Factors: The Cost of Living Longer
    • 3.2.2 Technological Developments: Making the Market Move Forward
    • 3.2.3 Economic Pressure: Treatment's Hefty Price Tag
    • 3.2.4 Political Issues: Governmental Involvement in Treatment

4 Leading Companies in Cancer Treating Drugs Market

  • 4.1 AstraZeneca Plc
    • 4.1.1 AstraZeneca Plc: Company Overview
    • 4.1.2 AstraZeneca Plc: Product Portfolio
    • 4.1.3 AstraZeneca Plc: Recent Developments
  • 4.2 Merck & Co. Inc.
    • 4.2.1 Merck & Co. Inc.: Company Overview
    • 4.2.2 Merck & Co. Inc.: Product Portfolio
    • 4.3.1 Merck & Co. Inc.: Recent Developments
  • 4.3 Novartis AG
    • 4.3.1 Novartis AG: Company Overview
    • 4.3.2 Novartis AG: Product Portfolio
    • 4.3.3 Novartis AG: Recent Developments
  • 4.4 Amgen Inc.
    • 4.4.1 Amgen Inc.: Company Overview
    • 4.4.2 Amgen Inc.: Product Portfolio
    • 4.4.3 Amgen Inc.: Recent Developments
  • 4.5 BRISTOL-MYERS SQUIBB
    • 4.5.1 BRISTOL-MYERS SQUIBB: Company Overview
    • 4.5.2 BRISTOL-MYERS SQUIBB: Product Portfolio
    • 4.5.3 BRISTOL-MYERS SQUIBB: Recent Developments
  • 4.6 GlaxoSmithKline PLC (GSK Consumer Care)
    • 4.6.1 GlaxoSmithKline PLC: Company Overview
    • 4.6.1 GlaxoSmithKline PLC: Product Portfolio
    • 4.6.2 GlaxoSmithKline PLC: Recent Developments
  • 4.7 Johnson & Johnson
    • 4.7.1 Johnson & Johnson: Company Overview
    • 4.7.2 Johnson & Johnson: Product Portfolio
    • 4.7.3 Johnson & Johnson: Recent Developments
  • 4.8 F. HOFFMANN-LA ROCHE AG
    • 4.8.1 F. Hoffmann-La Roche: Company Overview
    • 4.8.2 F. Hoffmann-La Roche: Product Portfolio
    • 4.8.3 F. Hoffmann-La Roche: Recent Developments
  • 4.9 Eli Lilly and Company
    • 4.9.1 Eli Lilly and Company: Company Overview
    • 4.9.2 Eli Lilly and Company: Product Portfolio
    • 4.9.3 Eli Lilly and Company: Recent Developments
  • 4.10 Celgene Corporation
    • 4.10.1 Celgene Corporation: Company Overview
    • 4.10.2 Celgene Corporation: Product Portfolio
    • 4.10.3 Celgene Corporation: Recent Developments
  • 4.11 Pfizer Inc.
    • 4.11.1 Pfizer Inc.: Company Overview
    • 4.11.2 Pfizer Inc.: Product Portfolio
    • 4.11.3 Pfizer: Recent Developments
  • 4.12 Astellas Pharma, Inc.
    • 4.12.1 Astellas Pharma, Inc.: Company Overview
    • 4.12.2 Astellas Pharma, Inc.: Recent Development
  • 4.13 Abbott Laboratories Inc.
    • 4.13.1 Abbott Laboratories Inc.: Company Overview
    • 4.13.2 Abbott Laboratories Inc.: Product Portfolio
    • 4.13.3 Abbott Laboratories Inc.: Recent Development
  • 4.14 AbbVie Inc.
    • 4.14.1 AbbVie Inc.: Company Overview
    • 4.14.2 AbbVie Inc.: Product Portfolio
    • 4.14.3 AbbVie: Recent Development
  • 4.15 Sanofi S.A. (Sanofi Genzyme)
    • 4.15.1 Sanofi S.A.: Company Overview
    • 4.15.2 Sanofi S.A.: Product Portfolio
    • 4.15.3 Sanofi S.A.: Recent Development
  • 4.16 Takeda Pharmaceutical Company Ltd.
    • 4.16.1 Takeda Pharmaceutical Company Ltd.: Company Overview
    • 4.16.2 Takeda Pharmaceutical Company Ltd.: Product Portfolio
    • 4.16.3 Takeda Pharmaceutical Company Ltd.: Recent Developments
  • 4.17 Gilead Science, Inc.
    • 4.17.1 Gilead Science, Inc.: Company Overview
    • 4.17.2 Gilead Science, Inc.: Product Portfolio
    • 4.17.3 Gilead Science, Inc.: Recent Developments
  • 4.18 A. Menarini Industrie Farmaceutiche Riunite Srl
    • 4.18.1 A. Menarini Industrie Farmaceutiche Riunite Srl: Company Overview
    • 4.18.2 A. Menarini Industrie Farmaceutiche Riunite Srl: Recent Developments
  • 4.19 FRESENIUS KABI AG
    • 4.19.1 FRESENIUS KABI AG: Product Portfolio
    • 4.19.2 FRESENIUS KABI AG: Recent Developments
  • 4.20 GRIFOLS S.A.
  • 4.21 Boehringer Ingelheim GMBH
    • 4.21.1 Boehringer Ingelheim GMBH: Company Overview
    • 4.21.2 Boehringer Ingelheim GMBH: Product Portfolio
    • 4.21.3 Boehringer Ingelheim GMBH: Recent Developments
  • 4.22 Sun Pharmaceutical Industries Ltd.
    • 4.22.1 Sun Pharmaceutical Industries Ltd.: Company Overview
    • 4.22.2 Sun Pharmaceutical Industries Ltd.: Product Portfolio
    • 4.22.3 Sun Pharmaceutical Industries Ltd.: Recent Developments
  • 4.23 Teva Pharmaceutical Industries Ltd.
    • 4.23.1 Teva Pharmaceutical Industries Ltd.: Company Overview
    • 4.23.2 Teva Pharmaceutical Industries Ltd.: Product Portfolio
    • 4.23.3 Teva Pharmaceutical Industries Ltd.: Recent Developments
  • 4.24 Valeant Pharmaceuticals International, Inc.
    • 4.24.1 Valeant Pharmaceuticals International, Inc.: Company Overview
    • 4.24.2 Valeant Pharmaceuticals International, Inc.: Product Portfolio
    • 4.24.3 Valeant Pharmaceuticals International, Inc.: Recent Developments
  • 4.25 ZIOPHARM Oncology, Inc.
    • 4.25.1 ZIOPHARM Oncology, Inc.: Company Overview
  • 4.26 Sorrento Therapeutics, Inc.
    • 4.26.1 Sorrento Therapeutics, Inc.: Company Overview
    • 4.26.2 Sorrento Therapeutics, Inc.: Recent Developments
  • 4.27 Aurora Biopharma, Inc.
    • 4.27.1 Aurora Biopharma, Inc.: Company Overview
  • 4.28 Tessa Therapeutics Pte Ltd.
    • 4.28.1 Tessa Therapeutics Pte Ltd.: Company Overview
    • 4.28.2 Tessa Therapeutics Pte Ltd.: Recent Developments
  • 4.29 Jounce Therapeutics, Inc.
    • 4.29.1 Jounce Therapeutics, Inc.: Company Overview
    • 4.29.2 Jounce Therapeutics, Inc.: Recent Developments
  • 4.30 Mylan N.V.
    • 4.30.1 Mylan N.V.: Company Overview
    • 4.30.1 Mylan N.V.: Recent Developments

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form
Back to Top
전화 문의
F A Q